Clinical Trial For Prostate Cancer Uses Ultrasound Technology, Indiana
University School Of Medicine

Article Date: 15 Dec 2005

A minimally invasive procedure using sound waves to destroy the tissue
of the prostate gland is being tested for men with recurrent prostate
cancer at the Indiana University School of Medicine.

The clinical trial utilizes High Intensity Focused Ultrasound
administered by the Sonablate® 500 to destroy the targeted tissue of
the prostate gland without affecting surrounding healthy tissue. Tissue
in the prostate gland is rapidly heated in a matter of seconds by
delivering HIFU energy with an ultrasound probe. The treatment usually
is performed as an outpatient procedure.

Principal investigators of the study at the IU School of Medicine are
Michael Koch, M.D., professor and chairman of the Department of
Urology, and Thomas A. Gardner, M.D., associate professor of urology.

Participants in the study must be between 40 and 80 years of age and
have previously had radiation or brachytherapy to treat prostate
cancer. To qualify participants must also have cancer stage T1 or T2
confined to the prostate gland and have a Gleason score of less than or
equal to 7.

For more information about the clinical trial see
http://www.ushifu.com/trials.asp.